Stay updated on Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.

Latest updates to the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page
- Check5 days agoChange DetectedA new revision tag indicates the record was updated administratively, moving from v3.5.4 to v3.5.5.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe study record history shows the trial was terminated by the sponsor due to lack of efficacy, with updates to Study Status and Recruitment Status reflected across the page. The latest version adds a 'Results Posted' indicator and references the revised record (Revision: v3.5.4) dated 2026-05-12.SummaryDifference0.9%

- Check40 days agoChange DetectedThe record history adds a new revision entry (v3.5.3). It replaces the previous v3.5.2 and indicates an administrative update to the study record.SummaryDifference0.1%

- Check54 days agoChange DetectedVersion 3.5.2 adds comprehensive study data sections (Adverse Events, Outcome Measures, Baseline Characteristics, Participant Flow, IPDSharing, Eligibility, Arms and Interventions, Study Design, Study Description, Study Status, Study Identification, Recruitment Status). It updates the revision timeline to reflect the new changes (Revision: v3.5.2, dated 2026-03-25).SummaryDifference2%

- Check69 days agoChange DetectedThe history now shows 'Results Submitted' replacing 'No Results Posted'. The entry updates the record to indicate that study results have been submitted.SummaryDifference0.1%

- Check83 days agoChange DetectedSite revision updated to v3.5.0, replacing the prior v3.4.3.SummaryDifference0.1%

Stay in the know with updates to Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ociperlimab and Tislelizumab vs Pembrolizumab in Lung Cancer Clinical Trial page.